https://orcid.org/0000-0003-0579-6709
References
- Coffin CS, Ramji A, Cooper CL, et al. Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. cmajo. 2019;7(4):E610–e617.
- Sant'Antonio E, Bonifacio M, Breccia M, et al. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019;187(3):286–295.
- Gill H, Leung GMK, Seto WK, et al. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. Ann Hematol. 2019;98(1):215–218.
- Perricone G, Vinci M, Pungolino E. Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis. 2017;49(6):719.
- Kirito K, Sakamoto M, Enomoto N. Elevation of the Hepatitis B Virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55(10):1341–1344.
- Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225–227.
- Hwang J, Lok A. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209–219.
- Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy. J Cin Oncol. 2015;33(19):2212–2220.
- Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202.
- Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Cin Oncol. 2014;32(33):3736–3743.
- Kusumoto S, Tobinai K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematology Am Soc Hematol Educ Program. 2014;2014(1):576–583.